Main Content
LIBRA: The liraglutide and Beta-cell Repair Study
Institutions involved: Mount Sinai Hospital
Investigators involved: Drs. Zinman and Retnakaran
Funding source: Novo Nordisk Canada
Inclusion criteria:
--Men or women between the ages of 30 and 75 inclusive with type 2 diabetes for 7 years or less.
--on no diabetes medication or oral diabetes medications only --HbA1c between 5.5% and 9% inclusive if on oral diabetes medications --HbA1c between 6.0% and 10% if on no diabetes medication
Brief abstract of project and relevance: In type 2 diabetes there is a progressive loss of function of the beta cells of the pancreas. These are the cells that make and secrete insulin which is the hormone primarily responsible for controlling blood sugar. In this study we want to assess if we are able to slow or reverse this from happening by using liraglutide (a new approved drug with beta-cell protective potential) vs placebo (an agent with no action) after a very short period of insulin therapy. Since high levels of blood sugar contribute to the loss of beta cell function, it is necessary to first normalize the blood sugar levels using insulin before we can evaluate the beta cell function. This study may demonstrate an important beta cell protective capacity of liraglutide. (see above for action of liraglutide)
Rationale for posting: for recruitment
Ethical Approval: Mount Sinai Hospital Research Ethics Board
Project start date: already underway
Project end date: approximately 1 year
For more information please call Haysook Choi, Research Nurse at 416-586-8778 or ) or visit our website at http://www.mountsinai.on.ca/care/lscd/research-studies